Which stocks are moving after the closing bell on Monday? After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Ardelyx Inc (NASDAQ:ARDX) Surges 11.6% After Q2 2025 Earnings and Revenue Beat Estimates Ardelyx (ARDX) Q2 2025 earnings beat estimates with $97.7M revenue (+33% YoY) and -$0.08 EPS. Strong IBSRELA & XPHOZAH sales drove growth, sparking an 11.6% after-hours stock surge.
Ardelyx Beats Q3 Sales Estimates, Shares Climb Ardelyx reported its third-quarter results after Thursday's closing bell. Here's a look at the details from the report:
Get insights into the top gainers and losers of Thursday's after-hours session. The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.
Ardelyx Stock Rises After-Hours On Q4 Beat, Drug Sales Outlook: Retail Gets Big Dose Of Optimism Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah.
Ardelyx Tops Estimates as Sales Surge The biopharma reported strong revenue growth in the fourth quarter thanks to solid performances from both of its approved products, Ibsrela and Xphozah.
Palantir Rally Loses Steam, Walmart Outlook Disappoints: What's Driving Markets Thursday? Stocks tumbled Thursday, with all major indices in the red, one day after the S&P 500 notched another all-time high in Wednesday’s trading session.
Get Your Money Out of These 3 Biotech Stocks Before the End of July These stocks are at a risk of providing negative returns to shareholders due to the several operational challenges faced by the companies.
Ardelyx Files Lawsuit Over Medicare Drug Payment Rules, Claims It Will Limit Patient Access To Kidney Disease Treatment Ardelyx challenges CMS in a lawsuit over Medicare's inclusion of Xphozah in bundled payments, affecting kidney disease drug accessibility.
